Prostate cancer and curcumin - Add spice to your life

[1] The convergence of cancer prevention and therapy in early-phase clinical drug development [J]. CANCER CELL, 2004, 6 (04) : 321 - 326

[2] From chemoprevention to chemotherapy: common targets and common goals [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (10) : 1327 - 1338

[3] Aggarwal BB, 2003, ANTICANCER RES, V23, P363

[4] Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and Akt activation [J]. MOLECULAR PHARMACOLOGY, 2006, 69 (01) : 195 - 206

[5] Curcumin is an in vivo inhibitor of angiogenesis [J]. MOLECULAR MEDICINE, 1998, 4 (06) : 376 - 383

[6] Nuclear factor-κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis [J]. BLOOD, 2004, 103 (08) : 3175 - 3184

[7] Curcumin (diferuloylmethane) inhibits receptor activator of NF-kB ligand-induced NF-kB activation in osteoclast precursors and suppresses osteoclastogenesis [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (10) : 5940 - 5947

[8] Curcurnin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells [J]. JOURNAL OF IMMUNOLOGY, 2003, 171 (07) : 3863 - 3871

[9] Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer [J]. ONCOGENE, 2001, 20 (50) : 7342 - 7351

[10] NF-κB activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer [J]. MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (08) : 2862 - 2870

[1] The convergence of cancer prevention and therapy in early-phase clinical drug development [J]. CANCER CELL, 2004, 6 (04) : 321 - 326

[2] From chemoprevention to chemotherapy: common targets and common goals [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (10) : 1327 - 1338

[3] Aggarwal BB, 2003, ANTICANCER RES, V23, P363

[4] Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and Akt activation [J]. MOLECULAR PHARMACOLOGY, 2006, 69 (01) : 195 - 206

[5] Curcumin is an in vivo inhibitor of angiogenesis [J]. MOLECULAR MEDICINE, 1998, 4 (06) : 376 - 383

[6] Nuclear factor-κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis [J]. BLOOD, 2004, 103 (08) : 3175 - 3184

[7] Curcumin (diferuloylmethane) inhibits receptor activator of NF-kB ligand-induced NF-kB activation in osteoclast precursors and suppresses osteoclastogenesis [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (10) : 5940 - 5947

[8] Curcurnin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells [J]. JOURNAL OF IMMUNOLOGY, 2003, 171 (07) : 3863 - 3871

[9] Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer [J]. ONCOGENE, 2001, 20 (50) : 7342 - 7351

[10] NF-κB activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer [J]. MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (08) : 2862 - 2870